Literature DB >> 19945477

A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test.

Valentina Gigliucci1, Kathleen Niamh Buckley, John Nunan, Karen O'Shea, Andrew Harkin.   

Abstract

The present study determined regional serotonin (5-HT) synthesis and metabolism changes associated with the nitric oxide synthase (NOS) inhibitor N(G)-nitro-L-arginine (L-NA) and the influence of 5-HT receptor blockade in the antidepressant-like actions of L-NA in the forced swimming test (FST). Regional effects of L-NA (5,10 and 20mg/kg i.p.) on tryptophan hydroxylase (TPH) activity, the rate limiting enzyme for 5-HT synthesis, were determined by measuring accumulation of the transient intermediate 5-hydoxytryptophan (5-HTP) following in vivo administration of the amino acid decarboxylase inhibitor, NSD 1015 (100mg/kg). L-NA (5-20mg/kg) dose dependently increased 5-HTP accumulation, particularly in the amygdaloid cortex, following exposure to the FST. L-NA also provoked an increase in regional brain 5-HIAA concentrations and in the 5-HIAA:5-HT metabolism ratio. Co-treatment with NSD-1015 failed to consistently modify the antidepressant-like effects of L-NA in the FST. Sub-active doses of L-NA (1mg/kg) and the 5-HT re-uptake inhibitor fluoxetine (2.5mg/kg) acted synergistically to increase swimming in the test. Co-treatment with the non-selective 5-HT receptor antagonist metergoline (1, 2 and 4mg/kg), attenuated the L-NA (20mg/kg)-induced reduction in immobility and increase in swimming behaviours. Metergoline alone however provoked an increase in immobility and reduction in swimming behaviours in the test. A similar response was obtained following co-treatment with the preferential 5-HT(2A) receptor antagonist ketanserin (5mg/kg) and the 5-HT(2C) receptor antagonist RO-430440 (5mg/kg). Co-treatment with the 5-HT(1A) receptor antagonist WAY 100635 (0.3mg/kg) or the 5-HT(1B) receptor antagonist GR 127935 (4mg/kg) failed to influence the antidepressant-like activity of L-NA. Taken together these data provide further support for a role for 5-HT in the antidepressant-like properties of NOS inhibitors. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945477     DOI: 10.1016/j.pbb.2009.11.007

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Antidepressant-like effects induced by NMDA receptor blockade and NO synthesis inhibition in the ventral medial prefrontal cortex of rats exposed to the forced swim test.

Authors:  Vitor Silva Pereira; Angélica Romano; Gregers Wegener; Sâmia R L Joca
Journal:  Psychopharmacology (Berl)       Date:  2015-01-16       Impact factor: 4.530

2.  Neuronal NOS inhibitor and conventional antidepressant drugs attenuate stress-induced fos expression in overlapping brain regions.

Authors:  Michelle Silva; Daniele C Aguiar; Cassiano R A Diniz; Francisco Silveira Guimarães; Sâmia R L Joca
Journal:  Cell Mol Neurobiol       Date:  2011-11-27       Impact factor: 5.046

3.  Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism.

Authors:  Valentina Gigliucci; Grainne O'Dowd; Sheena Casey; Danielle Egan; Sinead Gibney; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

4.  Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice.

Authors:  Marika V Doucet; Hester Levine; Kumlesh K Dev; Andrew Harkin
Journal:  Neuropsychopharmacology       Date:  2013-02-27       Impact factor: 7.853

5.  Regional Specific Modulation of Stress-Induced Neuronal Activation Associated with the PSD95/NOS Interaction Inhibitor ZL006 in the Wistar Kyoto Rat.

Authors:  Eoin Sherwin; Aifric Lennon; Andrew Harkin
Journal:  Int J Neuropsychopharmacol       Date:  2017-10-01       Impact factor: 5.176

Review 6.  Neuronal nitric oxide synthase and affective disorders.

Authors:  Qi-Gang Zhou; Xian-Hui Zhu; Ashley D Nemes; Dong-Ya Zhu
Journal:  IBRO Rep       Date:  2018-11-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.